Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Eledon Pharmaceuticals Inc
ELDN
Healthcare
Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular...
pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ELDN)
New Post
View:
Posts & Comments
Threaded Posts
(267)
•••
whytestocks
X
Post by
whytestocks
on Oct 29, 2024 11:15am
Eledon Pharmaceuticals Announces Positive Initial Data from
NEWS: $ELDN Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
...more
(267)
•••
whytestocks
X
Post by
whytestocks
on May 07, 2024 7:00pm
Eledon Announces Clinical Progress with Tegoprubart in the P
News; $ELDN Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionFirst participant dosed in clinical trial at University of Chicago Medicine assessing the use
...more
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 02, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(267)
•••
whytestocks
X
Post by
whytestocks
on Apr 22, 2024 12:45pm
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way i
NEWS: $ELDN Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage GainEledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is one of today's top gainers. The
...more
(15)
•••
HDavis
X
Post by
HDavis
on Nov 11, 2021 10:02pm
ELDN - Thursday Rundown, Friday Expectations
(5)
•••
SmallCapPaul
X
Post by
SmallCapPaul
on Dec 11, 2020 4:17pm
Is a Cure for Diabetes Being Studied
Is a Cure for Diabetes Enetering Phase II Trials? https://www.channelchek.com/news-channel/Is_a_Cure_for_Diabetes_Being_Studied_
(5)
•••
SmallCapPaul
X
Post by
SmallCapPaul
on Nov 23, 2020 9:26pm
Functional Cure for T1D Discussion
Noble Capital Markets, Inc. Announces Type-1 Diabetes Day- The Beginning of the End; Close to a Cure? A Panel of World Experts Breaks it all Down in a Virtual Presentation https://www
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden
Debt-Free Cannabis Company Set for Next Stage of Growth
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Poin-of-Care Testing.
Unique Battery Metals opportunity in Quebec